Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [847]

Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2...

Dr Shanu Modi - Memorial Sloan Kettering Cancer Centre, Manhattan, USA

Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 expression ( Dr Shanu Modi - Memorial Sloan Kettering Cancer Centre, Manhattan, USA )

Comment:Trifluridine/tipiracil, bevacizumab + trifluridine/tipiracil provides...

Dr Cathy Eng- Vanderbilt-Ingram Cancer Center, Nashville, USA

Comment:Trifluridine/tipiracil, bevacizumab + trifluridine/tipiracil provides benefits for metastatic colorectal cancer patients ( Dr Cathy Eng- Vanderbilt-Ingram Cancer Center, Nashville, USA )

Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC

Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan

Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC ( Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan )

Comment: (RVd) ± , stem cell transplantation and R maintenance shows...

Dr Julie Gralow- Chief Medical Officer, ASCO

Comment: (RVd) ± , stem cell transplantation and R maintenance shows significance for newly diagnosed myeloma patients ( Dr Julie Gralow- Chief Medical Officer, ASCO )

Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast...

Shanu Modi- Memorial Sloan Ketting Cancer Center, Manhattan, USA

Phase 3 study shows HER2 therapy clinically meaningful for metastatic breast cancer patients ( Shanu Modi- Memorial Sloan Ketting Cancer Center, Manhattan, USA )

(RVd) ± , stem cell transplantation and R maintenance shows significance for...

Dr Paul Richardson- Dana Farber Cancer Institute, Boston, USA

(RVd) ± , stem cell transplantation and R maintenance shows significance for newly diagnosed myeloma patients ( Dr Paul Richardson- Dana Farber Cancer Institute, Boston, USA )

Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM: Phase 3...

Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA

Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM: Phase 3 DETERMINATION trial ( Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA )

Trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil provides...

Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan

Trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil provides benefits for metastatic colorectal cancer patients ( Dr Takayuki Yoshino - National Cancer Center Hospital East, Kashiwa, Japan )

Ibrutinib improves PFS by 50% for older patients with newly diagnosed mantle...

Dr Michael Wang - MD Anderson Cancer Center, Houston, USA

Ibrutinib improves PFS by 50% for older patients with newly diagnosed mantle cell lymphoma ( Dr Michael Wang - MD Anderson Cancer Center, Houston, USA )

Everolimus after surgery can improve outcomes in those with high-risk kidney...

Dr Christopher Ryan - OHSU Knight Cancer Institute, Portland, USA

Everolimus after surgery can improve outcomes in those with high-risk kidney cancer ( Dr Christopher Ryan - OHSU Knight Cancer Institute, Portland, USA )

Sacituzumab govitecan increases PFS for HR+/HER2- metastatic breast cancer

Dr Hope Rugo - University of California San Francisco, San Francisco, USA

Sacituzumab govitecan increases PFS for HR+/HER2- metastatic breast cancer ( Dr Hope Rugo - University of California San Francisco, San Francisco, USA )

The adverse events atlas, towards a strategy to predict synergistic adverse...

Prof Bart Westerman - Amsterdam UMC, Amsterdam, Netherlands

The adverse events atlas, towards a strategy to predict synergistic adverse events of combination therapies ( Prof Bart Westerman - Amsterdam UMC, Amsterdam, Netherlands )

More from ecancer